Pharmacotherapy for female sexuality. Debates and developments

Author/s Valentina Rossi, Daniela Botta, Francesca Tripodi, Roberta Rossi
Publishing Year 2018 Issue 2018/2 Language Italian
Pages 24 P. 5-28 File size 290 KB
DOI 10.3280/RSC2018-002001
DOI is like a bar code for intellectual property: to have more infomation click here

Below, you can see the article first page

If you want to buy this article in PDF format, you can do it, following the instructions to buy download credits

Article preview

FrancoAngeli is member of Publishers International Linking Association, Inc (PILA), a not-for-profit association which run the CrossRef service enabling links to and from online scholarly content.

The scientific interest for female sexuality has grown in the last years, leading to the research of new treatments in which pharmacological and psychotherapeutic therapies could be both implied. Debates around these developments have arisen between professionals who consider pharmaceuticals as allies for clinical work on sexual dysfunctions and others who take distance to the potential female sexuality medicalization. Critics are related mainly to the arbitrary definition of what is considered normal in sexuality, the uncertain efficacy and the potential side effects of pharmacologic treatments, the risk of medications abuse and the diffusion of mechanistic vision of sexuality. Despite the same concerns could be addressed to male sexuality medicalization as well, many clinicians thinks that female sexuality is more complex and, therefore, not treatable just with a pill. Several studies on different medications efficacy on female sexuality has been conducted, but results are still controversial. Nowadays, only two medications (flibanserin and ospemifene) have been approved by Food and Drug Administration (FDA). On flibanserin, the last one approved by FDA, there are still boundaries and the prescriptions amount is still low. A This review shows a difference between pharmacotherapy for males and females’ sexual health is highlighted in the present review. For males several solutions are already available and still increasing. Moreover, every new pill is welcomed on the scientific panorama. For females, cultural biases and double standards still seems to exist and could interfere with the work on female sexual health. The biopsychosocial approach is the gold standard in male and female sexual dysfunctions’ treatment. The availability of pharmaceutic solutions also for women could be very useful for clinical work; taking into account the other varia-bles as well.

Keywords: Sexual dysfunction; sexual therapy, female sexuality, medicalization, sexual medicine.

  1. American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). American Psychiatric Pub.
  2. Balon R., Clayton A.H. (2014). Female sexual interest/arousal disorder: A diagnosis out of thin air. Arch Sex Behav, 43: 1227-9.
  3. Balon R, Clayton A.H. (2015). Further commentary on DSM-5 FSIAD diagnosis. J Sex Med, 12: 576-579.
  4. Achilli C., Pundir J., Ramanathan P., Sabatini L., Hamoda H., Panay N. (2017). Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: A systematic review and meta-analysis. Fertility and Sterility, 107(2): 475-482.
  5. Aftab A., Chen C., McBride J. (2017). Flibanserin and its discontents. Archives of Women’s Mental Health, 20(2): 243-247.
  6. Alexander M.S., Rosen R.C., Steinberg S., Symonds T., Haughie S., Hultling C. (2011). Sildenafil in women with sexual arousal disorder following spinal cord injury. Spinal Cord, 49(2): 273-9.
  7. Althof S.E. (2013). Integrated and Combined Therapy. In Kirana P.S., Tripodi F., Reisman Y. et al., The EFS and ESSM Syllabus of Clinical Sexology. Amsterdam, Medix Publisher: 516-527.
  8. Balon R., Segraves R.T. (2017). Which emperor has new clothes? Biology versus psychology in the era of statistical magic. Journal of Sex & Marital Therapy, 43(3): 201-205. DOI: 10.1080/0092623X.2016.121602
  9. Basson R. (2000). The female sexual response: A different model. Journal of Sex &Marital Therapy, 26(1): 51-65. DOI: 10.1080/00926230027864
  10. Basson R. (2001). Female sexual response: the role of drugs in the management of sexual dysfunction. Obstetrics & Gynecology, 98(2): 350-353. DOI: 10.1016/S0029-7844(01)01452-
  11. Basson R., Brotto L.A. (2003). Sexual psychophysiology and effects of sildenafil citrate in estrogenised women with acquired genital arousal disorder and impaired orgasm: A randomised controlled trial. BJOG: An International Journal of Obstetrics & Gynecology, 110(11): 1014-1024. DOI: 10.1016/S1470-0328(03)02938-
  12. Basson R., Berman J., Burnett A., Derogati L., Ferguson D., Fourcroy J., Goldstein I., Graziottin A., Heiman J., Laan E., Leiblum S., Padma-Nathan H., Rosen R., Segraves K., Segraves R.T., Shabsigh R., Sipski M., Wagner G., Whipple B. (2000). Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. The Journal of Urology, 163(3): 888-893. DOI: 10.1016/S0022-5347(05)67828-
  13. Basson R., Brotto L.A., Petkau J.A., Fabrie F. (2010). Role of androgens in women’s sexual dysfunction. Menopause, 17(5): 962-971.
  14. Basson R., Young A., Brotto L.A., Driscoll M., Corriea S., Labrie F. (2015). Is there a correlation between androgen and sexual desire in women? Letter to the editor. Journal of Sexual Medicine, 12(7): 1654-5.
  15. Behnia B., Heinrichs M., Bergmann W., Jung S., Germann J., Schedlowski M., Hartmann U., Kruger T.H. (2014). Differential effects of intranasal oxytocin on sexual experiences and partner interactions in couples. Horm Behav, 65: 308-318.
  16. Belkin Z.R., Krapf J.M., Goldstein A.T. (2015). Drugs in early clinical development for the treatment of female sexual dysfunction. Expert Opinion on Investigational Drugs, 24(2): 159-167. DOI: 10.1517/13543784.2015.97828
  17. Bernorio R., Piloni S., Mori G., Prunas A., Bosoni D., Nappi R.E. (2018). Efficacy and tolerability of a spray formulation containing Visnadine in women self-reporting sexual symptoms: a randomized double-blind placebo-controlled pilot study. Journal of Endocrinological Investigation, 41(6): 729-737.
  18. Berry M.D., Berry P.D. (2013). Contemporary treatment of sexual dysfunction: Reexamining the biopsychosocial model. The Journal of Sexual Medicine, 10(11): 2627-2643.
  19. Bloemers J., van Rooij K., Poels S., Goldstein I., Everaerd W., Koppeschaar H., Chivers M., Gerritsen J., van Ham D., Olivier B., Tuiten A. (2013). Toward personalized sexual medicine (part 1): Integrating the “dual control model” into differential drug treatments for hypoactive sexual desire disorder and female sexual arousal disorder. The Journal of Sexual Medicine, 10(3): 791-809.
  20. Bottari A., Belcaro G., Ledda A., Luzzi R., Cesarone M.R., Dugall M. (2013). Lady Prelox(R) improves sexual function in generally healthy women of reproductive age. Minerva Ginecol, 65: 435-444.
  21. Brotto L.A. (2017). Evidence-based treatmentsfor low sexual desire in women, Frontiers in Neuroendocrinology.
  22. Brotto L.A. (2015). Flibanserin. Archives of Sexual Behavior, 44(8): 2103-2105.
  23. Brotto L.A., Basson R., Chivers M.L., Graham C.A., Pollock P., Stephenson K.R. (2017). Challenges in designing psychological treatment studies for sexual dysfunction. Journal of Sex & Marital Therapy, 43(3): 191-200. DOI: 10.1080/0092623X.2016.121229
  24. Cacchioni T. (2015). Big pharma, women, and the labour of love. University of Toronto Press. DOI: 10.1111/1467-9566.1242
  25. Cacchioni T., Tiefer L. (2012). Why medicalization? Introduction to the special issue on the medicalization of sex. Journal of Sex Research, 49(4): 307-310. DOI: 10.1080/00224499.2012.69011
  26. Caruso S., Rugolo S., Agnello C., Intelisano G., Di Mari L., Cianci A. (2006). Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study. Fertil Steril, 85(5): 1496-501.
  27. Caruso S., Cianci S., Cariola M., Fava V., Rapisarda A., Cianci A. (2016). Effects of nutraceuticals on quality of life and sexual function of perimenopausal women, J Endocrinol Invest.
  28. Caruso S., Cicero C., Romano M., Presti L.L., Ventura B., Malandrino C. (2012). Tadalafil 5 mg daily treatment for type 1 diabetic premenopausal women affected by sexual genital arousal disorder. The Journal of Sexual Medicine, 9(8): 2057-2065.
  29. Caruso S., Malandrino C. (2013). Menopause and female sexuality. In: Kirana P.S., Tripodi F., Reisman Y., Porst H. (Eds), The EFS and ESSM Syllabus of Clinical Sexology. Medix Publisher Amsterdam.
  30. Caruso S., Mauro D., Cariola M., Fava V., Rapisarda A.M.C., Cianci A. (2018). Randomized crossover study investigating daily versus on-demand vulvar Visnadine spray in women affected by female sexual arousal disorder. Gynecological Endocrinology, 34(2): 110-114. DOI: 10.1080/09513590.2017.1354366
  31. Chivers M.L., Rosen R.C. (2010). Phosphodiesterase type 5 inhibitors and female sexual response: Faulty protocols or paradigms? Journal of Sexual Medicine, 7(2): 858-872.
  32. Chivers M.L., Basson R., Brotto L.A., Graham C.A., Stephenson K.R. (2017). Statistical and epistemological issues in the evaluation of treatment efficacy of pharmaceutical, psychological, and combination treatments for women’s sexual desire difficulties. Journal of Sex & Marital Therapy, 43(3): 210-217. DOI: 10.1080/0092623X.2016.126653
  33. Clayton A.H., Pyke R.E. (2017). Standards in studies of psychotherapy and pharmacotherapy interventions for HSDD. Journal of Sex & Marital Therapy, 43(3): 206-209.
  34. Clayton A.H., Dennerstein L., Fisher W.A., Kingsberg S.A., Perelman M.A., Pyke R.E. (2010). Standards for clinical trials in sexual dysfunction in women: Research designs and outcomes assessment. The Journal of Sexual Medicine, 7(1pt2): 541-560.
  35. Constantine G., Graham S., Portman D.J., Rosen R.C., Kingsberg S.A. (2015). Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric, 18(2): 226-232. DOI: 10.3109/13697137.2014.95499
  36. Cui Y., Zong H., Yan H., Li N., Zhang Y. (2014). The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: A systematic review and meta‐analysis. The Journal Of Sexual Medicine, 11(2): 487-497.
  37. DasGupta R., Wiseman O.J., Kanabar G., Fowler C.J. (2004). Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. The Journal of Urology, 171(3): 1189-1193.
  38. Davis S., van der Mooren M.J., van Lunsen R.H.W., Lopes P., Ribot C., Rees M., Moufarege A., Rodenberg C., Buch A., Purdie D.W. (2006). The efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause, 13: 387.
  39. Davis S.R. (2011). Cardiovascular and cancer safety of testosterone in women. Current Opinion in Endocrinology, Diabetes and Obesity, 18(3): 198-203.
  40. Davis S.R., Worsley R., Miller K.K., Parish S.J., Santoro N. (2016). Androgens and female sexual function and dysfunction-findings from the Fourth International Consultation of Sexual Medicine. The Journal of Sexual Medicine, 13(2): 168-178.
  41. Dennerstein L., Koochaki P., Barton I., Graziottin, A. (2006). Hypoactive sexual desire disorder in menopausal women: A survey of western European women. Journal of Sexual Medicine, 3(2): 212-222.
  42. Derogatis L.R., Komer L., Katz M., Moreau M., Kimura T., Garcia M. Jr, Wunderlich G., Pyke R. (2012). Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study. J Sex Med, 9: 1074- 1085.
  43. Dooley E.M., Miller M.K., Clayton A.H. (2017). Flibanserin: From Bench to Bedside. Sexual Medicine Reviews.
  44. Edney A., Colby L. (2015). Valeant’s newest problem: The female libido pill isn’t selling. The Globe and Mail.
  45. Farmer M., Yoon H., Goldstein I. (2016). Future targets for female sexual dysfunction. The Journal of Sexual Medicine, 13(8): 1147-1165.
  46. Gao L., Yang L., Qian S., Li T., Han P., Yuan J. (2016). Systematic review and meta‐analysis of phosphodiesterase type 5 inhibitors for the treatment of female sexual dysfunction. International Journal of Gynecology & Obstetrics, 133(2): 139-145.
  47. Gao Z., Yang D., Yu L., Cui Y. (2015). Efficacy and safety of flibanserin in women with hypoactive sexual desire disorder: a systematic review and meta-analysis. The Journal of Sexual Medicine, 12(11): 2095-2104.
  48. Goldstein I. (2007). Commentary-Will Medical Solutions to Sexual Problems Make Sexological Care and Science Obsolete?. Journal of Sex & Marital Therapy, 33(5): 439-441. DOI: 10.1080/0092623070147716
  49. Goldstein I. (2014). Effect of food and drug administration decisions on sexual medicine research. The Journal of Sexual Medicine, 11(11): 2623-2624.
  50. Goldstein S.R., Bachmann G.A., Koninckx P.R., Lin V.H., Portman D.J., Ylikorkala O., Ospemifene Study Group. (2014). Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric, 17(2): 173-182. DOI: 10.3109/13697137.2013.83449
  51. Graham C.A., Brotto L.A., Zucker K.J. (2014). Response to Balon and Clayton (2014): Female sexual interest/arousal disorder is a diagnosis more on a firm ground than thin air. Arch Sex Behav, 43: 1231-4.
  52. Graham C.A., Boynton P.M., Gould K. (2017). Women’s Sexual Desire. Challenging narratives of “dysfunction”. European Psychologist, 22(1): 27-38.
  53. Gutsche M., Burri A. (2017). What Women Want-An Explorative Study on Women’s Attitudes Toward Sexuality Boosting Medication in a Sample of Swiss Women. The Journal of Sexual Medicine, 14(3): 404-412.
  54. Houman J., Feng T., Eilber K.S., Anger J.T. (2016). Female Sexual Dysfunction: Is It a Treatable Disease?. Current Urology Reports, 17(4): 28.
  55. Jaspers L., Feys F., Bramer W.M., Franco O.H., Leusink P., Laan E.T. (2016). Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Internal Medicine, 176(4): 453-462.
  56. Jayne C.J., Heard M.J., Zubair S., Johnson D.L. (2017). New developments in the treatment of hypoactive sexual desire disorder–a focus on Flibanserin. International Journal of Women’s Health, 9: 171. DOI: 10.2147/IJWH.S12535
  57. Katz M., Derogatis L.R., Ackerman R., Hedges P., Lesko L., Garcia M. Jr, Sand M. (2013). Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med, 10: 1807-1815.
  58. Kenemans P., Bundred N.J., Foidart J.M., Kubista E., von Schoultz B., Sismondi P., Vassilopoulou-Sellin R., Yip C.H., Egberts J., Mol-Arts M., Mulder R., van Os S., Beckmann M.W. (2009). Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. The Lancet Oncology, 10(2): 135-146. DOI: 10.1016/S1470-2045(08)70341-
  59. Kingsberg S.A., Althof S.E. (2011). Satisfying sexual events as outcome measures in clinical trial of female sexual dysfunction. The Journal of Sexual Medicine, 8(12): 3262-3270.
  60. Laan E., Van Lunsen R.H.W., Everaerd W. (2001). The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric, 4(1): 28-41.
  61. Labrie F., Archer D., Bouchard C., Fortier M., Cusan L., Gomez J.L., Girard G., Baron M., Ayotte N., Moreau M., Dubé R., Côté I., Labrie C., Lavoie L., Berger L., Gilbert L., Martel C., Balser J. (2009). Effect of intravaginal dehydroepiandrosterone (prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause. 16(5): 923-31.
  62. Labrie F., Archer D., Bouchard C., Fortier M., Cusan L., Gomez J.L., Girard G., Baron M., Ayotte N., Moreau M., Dubé R., Côté I., Labrie C., Lavoie L., Gilbert L., Martel C., Balser J. (2014). Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. J Sex Med, 11: 1766-85.
  63. Labrie F., Archer D.F., Bouchard C., Girard G., Ayotte N., Gallagher J.C., Cusan L., Baron M., Blouin F., Waldbaum A.S., Koltun W., Portman D.J., Côté I., Lavoie L., Beauregard A., Labrie C., Martel C., Balser J., Moyneur É. (2015a). Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas, 81: 46-56.
  64. Labrie F., Derogatis L., Archer D.F., Koltun W., Vachon A., Young D., Frenette L., Portman D., Montesino M., Côté I., Parent J., Lavoie L., Beauregard A., Martel C., Vaillancourt M., Balser J., Moyneur É. (2015b). Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy. J Sex Med, 12: 2401-12.
  65. Labrie F., Montesino M., Archer, D.F., Lavoie L., Beauregard A., Côté I., Martel C., Vaillancourt M., Balser J., Moyneur E. (2015c). Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner. Climacteric, 18: 817–25. DOI: 10.3109/13697137.2015.107750
  66. Leddy L.S., Yang C.C., Stuckey B.G., Sudworth M., Haughie S., Sultana S., Maravilla K.R. (2012). Influence of sildenafil on genital engorgement in women with female sexual arousal disorder. Journal of Sexual Medicine, 9(10): 2693-2697.
  67. Major S. (2004). Pfizer will not apply for a license for sildenafil for women. British Medical Journal, 328(7439): 542.
  68. Martins W.P., Lara L.A., Ferriani R.A., Rosa-E-Silva R., Figueiredo J.B., Nastri, C.O. (2014). Hormone therapy for female sexual function during perimenopause and postmenopause: a Cochrane review. Climacteric, 17(2): 133-135. DOI: 10.3109/13697137.2013.82868
  69. Meixel A., Yanchar E., Fugh-Berman A. (2015). Hypoactive sexual desire disorder: inventing a disease to sell low libido. Journal of medical ethics, 41(10): 859-862.
  70. Moynihan R. (2010). Merging of marketing and medical science: female sexual dysfunction. BMJ: British Medical Journal, 341.
  71. Moynihan R., Mintzes B. (2010). Sex, lies and pharmaceuticals. How drug companies plan to profit from female sexual dysfunction. Psychology & Sexuality, 4(2): 207-209. DOI: 10.1080/19419899.2013.77416
  72. Muin D.A. Wolzt M., Marculescu R., Sheikh Rezaei S., Salama M., Fuchs C., Luger A., Bragagna E., Litschauer B., Bayerle-Eder M. (2015). Effect of long-term intranasal oxytocin on sexual dysfunction in premenopausal and postmenopausal women: a randomized trial. Fertil Steril, 104(3): 715-723 e4.
  73. Nappi R.E., Cucinella L. (2015). Advances in pharmacotherapy for treating female sexual dysfunction. Expert Opinion on Pharmacotherapy, 16(6): 875-887. DOI: 10.1517/14656566.2015.102079
  74. Nappi R.E., Palacios S. (2014). Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric, 17(1): 3-9. DOI: 10.3109/13697137.2013.87169
  75. Nappi R.E., Albani F., Santamaria V., Tonani S., Martini E., Terreno E., Brambilla E., Polatti F. (2010). Menopause and sexual desire: The role of testosterone. Menopause International, 16: 162-168.
  76. Nurnberg H.G., Hensley P.L., Heiman J.R., Croft H.A., Debattista C., Paine S. (2008). Sildenafil treatment of women with antidepressant-associated sexual dysfunction: A randomized controlled trial. Journal of the American Medical Association, 300(4): 395-404.
  77. Palacios S., Cancelo M.J. (2016). Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy. International Journal of Women’s Health, 8: 617. DOI: 10.2147/IJWH.S11003
  78. Parish S.J., Hahn S.R. (2016). Hypoactive sexual desire disorder: A review of epidemiology, biopsychology, diagnosis, and treatment. Sexual Medicine Review, 4(2): 103-120.
  79. Peixoto C.G., Carrilho J.A., Barros T.T.S.B., Ribeiro L.M., Silva A.E., Nardi A., Cardoso, Veras A.B. (2017). The effects of dehydroepiandrosterone on sexualfunction: a systematic review. Climacteric. DOI: 10.1080/13697137.2017.127914
  80. Perz J., Ussher J.M., Gilbert E. (2014). Feeling well and talking about sex: psycho-social predictors of sexual functioning after cancer. BMC Cancer, 14(1): 228. DOI: 10.1186/1471-2407-14-22
  81. Poels S., Bloemers J., van Rooij K., Goldstein I., Gerritsen J., van Ham D., van Mameren F., Chivers M., Everaerd W., Koppeschaar H., Olivier B., Tuiten A. (2013). Toward personalized sexual medicine (part 2): Testosterone combined with a PDE5 inhibitor increases sexual satisfaction in women with HSDD and FSAD, and a low sensitive system for sexual cues. Journal of Sexual Medicine, 10(3): 810-823.
  82. Porst H., Vardi Y., Akkus E., Melman A., Park N.C., Seftel A.D. (2010). Standards for clinical trials in male sexual dysfunctions. The Journal of Sexual Medicine, 7(1pt2): 414-444.
  83. Rahn D.D., Carberry C., Sanses T.V., Mamik M.M., Ward R.M., Meriwether K.V., Olivera C.K., Abed H., Balk E.M., Murphy M. (2014). Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstetrics and Gynecology, 124(6): 1147. DOI: 10.1097/AOG.000000000000052
  84. Reed B.G., Bou Nemer L., Carr B.R. (2016). Has testosterone passed the test in premenopausal women with low libido? A systematic review. International Journal of Women’s Health, 8: 599-607. DOI: 10.2147/IJWH.S11621
  85. Reisman Y., Gianotten W. (2017). Cancer, Intimacy and Sexuality – A Practical Approach. Berlin: Springer.
  86. Roehr B. (2015). FDA committee recommends approval for “female Viagra”. BMJ: British Medical Journal, 350.
  87. Sahebkar A., Saadat S.H., Panahi Y., Kabir A., Rahmani K., Hosseinialhashemi M. (2016). Systematic review and meta-analysis of flibanserin’s effects and adverse events in women with hypoactive sexual desire disorder. Current Drug Metabolism, 18(1): 78-85. DOI: 10.2174/138920021766616102609033
  88. Segal J.Z. (2012). The sexualization of the medical. Journal of Sex Research, 49(4): 369-378. DOI: 10.1080/00224499.2011.65360
  89. Shifren J.L., Braunstein G.D., Simon J.A., Casson P.R., Buster J.E., Redmond G.P. (2000). Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med, 343: 682-8. 
 DOI: 10.1056/NEJM20000907343100
  90. Shifren J.L., Monz B.U., Russo P.A., Segreti A., Johannes C.B. (2008). Sexual problems and distress in United States women: prevalence and correlates. Obstetrics & Gynecology, 112(5): 970-978.
  91. Simon J.A., Goldstein I., Kim N.N., Freedman M.A., Parish S.J. (2016). Flibanserin Approval: Facts or Feelings? Sexual Medicine, 4(2): e69.
  92. Simonelli C., Rossi R., Forleo R. (2003). Le disfunzioni sessuali femminili. Encyclopédie Médico-Chirurgicale, Ginecologia-Ostetricia, I – 166-A-10
  93. Sungur M.Z., Gündüz A. (2014). A comparison of DSM‐IV‐TR and DSM‐5 definitions for sexual dysfunctions: critiques and challenges. The Journal of Sexual Medicine, 11(2): 364-373.
  94. Thorp J., Simon J., Dattani D., Taylor L., Kimura T., Garcia M. Jr, Lesko L., Pyke R. (2012). Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med, 9: 793-804.
  95. Tiefer L. (2010). Activism on the medicalization of sex and female genital cosmetic surgery by the New View Campaign in the United States. Reproductive Health Matters, 18(35): 56-63. DOI: 10.1016/S0968-8080(10)35493-
  96. Tiefer L. (2012). Medicalizations and demedicalizations of sexuality therapies. Journal of Sex Research, 49(4): 311-318. DOI: 10.1080/00224499.2012.67894
  97. Tiefer L. (2017). Apples and oranges: “Sexual Medicine” and the effort to deny that counting and classifying are political acts. Journal of Sex & Marital Therapy, 43(3): 246-249. DOI: 10.1080/0092623X.2016.123016
  98. Tripodi F., Rossi V., Botta D. (2017). Psicoterapia del disturbo dell’interesse e dell’eccitazione sessuale femminile. In Jannini E.A., Lenzi A., Maggi M., a cura di, Sessuologia medica. Trattato di psicosessuologia, medicina della sessualità e salute della coppia. Milano: Edra.
  99. van der Made F., Bloemers J., Yassem W.E., Kleiverda G., Everaerd W., van Ham D., Oliver B., Koppeschaar H., & Tuiten A. (2009). The influence of testosterone combined with a PDE5-inhibitor on cognitive, affective, and physiological sexual functioning in women suffering from sexual dysfunction. Journal of Sexual Medicine, 6: 777-790.
  100. Wierman M.E., Nappi R.E., Avis N., Davis S.R., Labrie F., Rosner W., (2010). Endocrine aspects of women’s sexual function. Journal of Sexual Medicine, 7(1pt2): 561-585.

  101. Wylie K.R. (2010). Female sexual dysfunction: reality or disease-mongering?. British Journal of Hospital Medicine, 71(8): 426.

Valentina Rossi, Daniela Botta, Francesca Tripodi, Roberta Rossi, Farmaci per la sessualità femminile. Dibattiti e sviluppi in "RIVISTA DI SESSUOLOGIA CLINICA" 2/2018, pp 5-28, DOI: 10.3280/RSC2018-002001